Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - ALL

Join Dan Douer, MD and Jae Park, MD from Memorial Sloan Kettering Cancer Center as they present their multidisciplinary expertise on a range of cases pertaining to acute lymphoblastic leukemia (ALL).

ALL is a heterogeneous hematologic disease characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs. The NCCN Guidelines stratify patients with ALL by the presence of the Philadelphia chromosome and then by age, with adolescents and young adults defined as those between the ages of 15 and 39 years and adults defined as 40 years of age and older. The NCCN Guidelines further classify ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; and supportive care considerations.

There are subsets of patients for whom current treatment options remain ineffective. Survival outcomes are poor when the disease is relapsed/refractory, and even in patients with relapsed/refractory disease who achieve a complete response, the majority will not be durable. Therefore, improvement in the treatment options for this subset of patients with ALL is necessary.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss the components of risk assessment and stratification for risk-adapted therapy
  • Summarize the current and emerging treatment options for acute lymphoblastic leukemia
Additional information
Supporters: 

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
12/16/2015
Course expires: 
12/16/2016
Cost:
$0.00

Dan Douer, MD
Memorial Sloan Kettering Cancer Center

Jae Park, MD
Memorial Sloan Kettering Cancer Center

Disclosure of Relevant Financial Relationships

All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Faculty Disclosures
The faculty listed below have disclosed the following relevant financial relationships:

Dan Douer, MD
Amgen Inc.: Grant/Research Support; Consulting Fees, Honoraria
Incyte: Grant/Research Support
Gilead: Grant/Research Support; Consulting Fees, Honoraria
Sigma Tau: Grant/Research Support; Consulting Fees, Honoraria
Spectrum: Consulting Fees, Honoraria

Jae Park, MD
Amgen Inc.: Consulting Fees, Honoraria
Juno Therapeutics: Scientific Advisor

NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:

Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Jennifer McCann Weckesser

The NCCN clinical information team listed below, who have reviewed content, has the following relevant financial relationships to disclose:

Courtney Smith, PhD
Johnson & Johnson: Equity Interest/Stock Options
Opko Health Inc: Equity Interest/Stock Options

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.75 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-15-148-H01-P

Available Credit

  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation

Accreditation Period

Course opens: 
12/16/2015
Course expires: 
12/16/2016

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader or other PDF reader software for certificate viewing/printing